Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM ESTCompany ParticipantsPeter Dannenbaum - Vice ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more ...

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Melatonin supplements have become a ubiquitous sleep aid, but research shows that benefits are modest, and the heart health ...

Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...

We are honored to introduce KEYTRUDA SC, the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered in one minute every three weeks or in two minutes every six ...

Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.

Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara's stock (CDTX) soaring 106% in recent morning trading, enough to make it the biggest gainer on the major U.S. exchanges. The ...